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Systematic deletions and point mutations in the C-terminal exten-
sion of mammalian PFK (phosphofructokinase) led us to identify
Leu-767 and Glu-768 of the M-type isoform (PFK-M) as the
motifs responsible for the role of this region in inhibition by
MgATP. These amino acids are the only residues of the C-terminus
that are conserved in all mammalian isoforms, and were found to
have a similar function in the C-type isoenzyme. Both residues
in PFK-C and Leu-767 in PFK-M were also observed to be criti-
cal for inhibition by citrate, which is synergistic with that by
MgATP. Binding studies utilizing titration of intrinsic protein fluo-
rescence indicated that the C-terminal part of the enzyme partici-
pates in the signal transduction route from the MgATP inhibitory
site to the catalytic site, but does not contribute to the binding of
this inhibitor, whereas it is essential for the binding of citrate. Mu-
tations of the identified structural motifs did not alter either the
action of other allosteric effectors that also interact with MgATP,
such as the inhibitor phosphoenolpyruvate and the strong activator
fructose 2,6-bisphosphate, or the co-operative effect of fructose
6-phosphate. The latter data provide evidence that activation by
fructose 2,6-bisphosphate and fructose 6-phosphate co-operati-
vity are not linked to the same allosteric transition as that medi-
ating inhibition by MgATP.
Key words: allosteric regulation, allosteric transition, enzyme
engineering, enzyme regulation, glycolysis, phosphofructokinase.
INTRODUCTION
PFK (phosphofructokinase; EC 2.7.1.11) catalyses the MgATP-
dependent phosphorylation of Fru-6-P (fructose 6-phosphate) to
fructose 1,6-bisphosphate. Its activity is highly modulated by the
binding of various allosteric effectors at different binding sites,
so that PFK is considered to play a basic role in the control of
glycolytic flux in most cells [1–3]. Mammalian PFK isoenzymes
exist as homo- and hetero-oligomers composed of three types of
subunit (C, M and L) that are encoded by distinct genes showing
tissue-specific expression [4]. Accordingly, PFK-M is the only
form in adult muscle, PFK-L is predominant in the liver, and
variable proportions of all three isoenzymes have been detected
in other cell types [4–6]. These isoenzymes were reported to dif-
fer in their regulatory properties [7–9]. Thus the C isoenzyme is
more sensitive to inhibition by MgATP than is PFK-M [7,9], but
less sensitive than the L isoform [7]. This is accompanied by a
corresponding difference in the apparent affinity for Fru-6-P, and
was proposed to contribute to the characteristic glycolytic function
in particular tissues [7–9]. In the absence of a three-dimensional
structure of eukaryotic PFK, assignment of amino acid residues
to substrate and effector sites has been made by sequence align-
ments with the less complex prokaryotic enzyme on the basis of
(i) the theory that PFK from eukaryotes appeared after dupli-
cation, fusion and divergence of an ancestral prokaryotic gene,
hence giving rise to new allosteric sites [10], and (ii) the available
X-ray crystal structures of the bacterial enzyme (reviewed in [11]).
To date, a few amino acids involved in the response to specific
ligands, such as the potent activator Fru-2,6-P2 (fructose 2,6-
bisphosphate) [12,13] and the inhibitors citrate [12] and MgATP
Abbreviations used: PFK, phosphofructokinase; Fru-6-P, fructose 6-phosphate; Fru-2,6-P2, fructose 2,6-bisphosphate; HmPFK and AtPFK, phospho-
fructokinases from human muscle and ascites tumour cells respectively.
1 To whom correspondence should be addressed (e-mail juanjose.aragon@uam.es).
[14], have been identified in mammalian PFKs by site-directed
mutagenesis.
Allosteric inhibition by MgATP is a key mechanism for the
regulation of the flux through PFK in eukaryotic cells. This in-
hibitory effect interacts with Fru-6-P co-operativity (sigmoidal
kinetics), increasing the S0.5 [2,15,16], and with activation by Fru-
2,6-P2, increasing the Kact [17], and is synergistic with inhibition
by other inhibitors, such as citrate and phosphoenolpyruvate [18],
thus allowing a finer modulation of PFK activity. Consequently,
identification of the structural elements involved in this regulatory
property is a major factor in accounting for the molecular basis of
PFK function. Mutation of Arg-429 and Arg-433 of mouse PFK-C
led to the proposal that the ATP inhibitory site evolved from
the duplicated phosphoenolpyruvate/ADP allosteric site of the
ancestral prokaryotic precursor [14]. This site would be located
within the sequence region that shows identity between the N- and
C-terminal halves of PFK-C, as well as between each of them
and the bacterial isoenzymes, and would be composed of residues
from both halves. This is similar to the Fru-2,6-P2 binding site,
which evolved from the duplicated catalytic site of the prokaryotic
enzyme [12,13] and is shared in the interface between two subunits
[10,11]. However, in addition to the proposed ATP binding site,
earlier work showed that the C-terminal region of the muscle
isoenzyme is essential for inhibition by ATP. Thus, from partial
proteolysis of rabbit muscle PFK-M, Valaitis et al. [19] identified
the sequence H763AHLEHISR as being critical for this property.
This sequence is located within the approx. 30-residue C-terminal
extension of the muscle enzyme compared with the similar region
of bacterial PFK, so the acquisition of this extension during
evolution was proposed to provide for this control mechanism
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Table 1 Synthetic oligodeoxynucleotides used to generate mutant PFKs
The introduced mutations are in bold face. SphI restriction sites are underlined. Stop codons are in bold italic.
Mutation Sequence
HmPFK-M
17 5′-GGGGCATGCTTATTAGTCTGAAGTGTCCAAGTCAAT-3′
12 5′-GGGGCATGCGGTACCTTATTACTCCAGGTGGGCATGGTC-3′
H764A/H766A/H769A 5′GGGGCATGCTTATTAGACGGCAGCTTCCCCGGACCGCTTCCGGGATGGCCTCCAGGGCGGCAGCGTCTGAAGTGTC-3′
L767A 5′-GGGCATGCTCGAGTTATTAGACGGCAGCTTCCCCGGACCGCTTCCGGGTGATGTGCTCGGCGTGGGCATGGTCTGA-3′
E768A 5′-GGGCATGCAGATCTTATTAGACGGCAGCTTCCCCGGACCGCTTCCGGGTGATGTGAGCCAGGTGGGCATGGTCTGA-3′
AtPFK-C
13 5′-GGGGCATGCTCATCAATCAGACATGTCATAGCTCGC-3′
4 5′-GGGGCATGCCTACTAGTGCTGCAAGGACTCCAG-3′
H780A 5′-GGGGCATGCTCATCATAGTTCTTCATGAGCCTGCAAGGA-3′
H781A 5′-CATAGTTCTTCAGCGTGCTGCAAGGA-3′
H780A/H781A 5′-GGGGCATGCTCATCATAGTTCTTCAGCAGCCTGCAAGGA-3′
L775A 5′-GGGGCATGCGAATTCATCATAGTTCTTCATGGTGCTGCAAGGACTCGGCCTTGCCTGAATC-3′
E776A 5′-GGGGCATGCTCGAGTCATCATAGTTCTTCATGGTGCTGCAAGGAAGCCAGCTTGCC-3′
L775A/E776A 5′-GGGGCATGCTCTAGAGTTCTTCATGGTGCTGCAAGGAAGCGGCCTTGCCTGAATC-3′
[19]. In fact, recently reported allosteric mutants of the non-
allosteric PFK from the slime mould Dictyostelium discoideum,
which lacks the C-terminal nonapeptide described above, still
failed to be inhibited by ATP [20]. The cluster of three histidines
present in this sequence was then suggested to contribute to the
binding of MgATP to the inhibitory site [19], since histidine
residues were implicated in this regulatory effect based on effects
of diethylpyrocarbonate modification of sheep heart PFK [21],
and later the Ascaris suum enzyme [22]. Additionally, unidentified
histidine residues were proposed to mediate the proton inhibition
of animal PFK [23], which is known to modify Fru-6-P affinity
[16] and co-operativity [15] and to enhance the binding of MgATP
to its inhibitory site [24].
The present work was initiated to investigate the role of
C-terminal histidine residues in the inhibition by ATP of mam-
malian PFK and, eventually, to identify the structural motifs of
this region responsible for this important property in two differ-
ent isoenzymes. Additionally, this led us to investigate the contri-
bution of the identified amino acid residues to the functioning of
other allosteric effectors whose mechanisms of action have been
connected with that of the inhibitor ATP.
MATERIALS AND METHODS
Materials
All chemical reagents and enzymes used in genetic assays and pro-
tein purification were obtained from Roche Molecular Biochem-
icals, Biotools, Amersham or Sigma. The SculptorTM In Vitro
Mutagenesis System for site-directed mutagenesis was purchased
from Amersham. Oligonucleotides were synthesized by Isogen.
The auxiliary enzymes and biochemicals for the PFK assay were
from Sigma. Other reagents were obtained from commercial
sources and were of the best grade available.
Strains, media and growth conditions
The Escherichia coli strains used for general cloning procedures
and amplifications of DNA were DH5α [SupE44 lacU169
(80 lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1]
and TG1 {supE hsd5 thi (lac-proAB) F′ [traD36 proAB+
lacIq lacZM15]}. The Saccharomyces cerevisiae strain HD152-
1D (MATα pkf1::HIS3 pfk2::HIS3 ura3-52, his3-1 leu2-3,112
trp1-289 MAL2-8c SUC2 GAL) [9], carrying deletions in both
yeast PFK genes, was used for the expression of wild-type and
mutant isoforms of PFK-M from human muscle (HmPFK-M)
and PFK-C from ascites tumour cells (AtPFK-C). E. coli was
grown on either liquid or solid LB medium [25], with appropriate
antibiotics added when required. Yeast manipulations were as
described previously [26].
Genetic manipulations, plasmids and in vitro mutagenesis
Point mutations and C-terminal deletions of HmPFK-M and
AtPFK-C at the desired positions were introduced into their res-
pective cDNAs by PCR (except for H781A of AtPFK-C; see
below) using mutagenic primers that carried an SphI site at
their 5′ end to facilitate subsequent subclonings (Table 1). The
double-stranded plasmids p18HmPFK and p18TPC [9], pUC18
derivatives carrying the cDNAs for HmPFK-M and AtPFK-C
respectively, were employed as templates. The amplification re-
action mixture contained 10–25 ng of template DNA, 0.2 mM
each dNTP, 25 pmol of sense (17-mer universal and 16-mer
reverse sequencing primers for HmPFK-M and AtPFK-C respect-
ively) and antisense mutagenic primers, 2.5 units of Taq DNA
polymerase and the buffer provided by the manufacturer in a
total volume of 100 µl. PCR was carried out for 30 cycles (94 ◦C,
1 min; 55 ◦C, 2 min; 72 ◦C, 2 min).
To obtain the mutant cDNAs of HmPFK-M downstream of the
PFK2 promoter of S. cerevisiae in the expression vector pJJH71
[26], the PCR products were first digested with EspI–SphI, then
the DNA fragments carrying the desired mutations at the 3′ end of
HmPFK cDNA were isolated by agarose gel electrophoresis and
used to replace the corresponding DNA sequence of wild-type pfk
in pJJH71PFK [27]. Mutant cDNAs of AtPFK-C were obtained by
cloning the respective ApaI–SphI-digested DNA fragments from
the mutagenic PCR reaction into ApaI–SphI-digested p18TPC.
The ClaI–SphI fragments from the resulting plasmids were used to
replace their counterparts in the pJJH71-derived plasmid pCHA1
[9], generating the recombinant plasmids in which the mutant pfk
genes were expressed under the control of the S. cerevisiae PFK2
promoter.
The cDNA for AtPFK-C carrying the H781A mutation was
generated by using the SculptorTM In Vitro Mutagenesis System.
Previously, the full-length cDNA of AtPFK-C was cloned in
M13mp18 as an EcoRI–KpnI 2.7 kbp fragment from λZTPC
[9], yielding plasmid pMTPC. Mutagenesis was performed as re-
commended by the manufacturer, using the mutagenic primer
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(Table 1) and single-stranded DNA derived form pMTPC as temp-
late; the ClaI–SphI DNA fragment from the resulting M13mp18
derivative was finally cloned into pCHA1, as described above.
Sequencing of the resulting plasmids by the dideoxynucleotide
chain termination method confirmed that only the desired mu-
tations had been introduced.
Expression and purification of recombinant enzymes
Wild-type and mutant isoforms of HmPFK-M and AtPFK-C
were functionally expressed in S. cerevisiae strain HD152-1D,
as yeast transformants with the corresponding plasmids comple-
mented the glucose-negative phenotype of the recipient strain.
For purification of the recombinant enzymes, yeast transformants
expressing either wild-type or mutant PFK were grown on 1 litre of
rich medium containing glucose to early stationary phase, harves-
ted by sedimentation and washed in buffer A (50 mM Tris/phos-
phate, 0.05 mM fructose 1,6-bisphosphate, 0.1 mM EDTA,
1 mM dithiothreitol, 50 mM NaF, 0.5 mM PMSF and 2.5 µg/ml
leupeptin, pH 8.0). Approx. 10–13 g of wet cells were resus-
pended in 2 vol. of buffer A, mixed with 5 vol. of glass beads and
shaken in a refrigerated mill for 5 min. After filtration, the beads
were washed with 1 vol. of buffer A. The filtrate was centrifuged
at 31000 g for 30 min at 4 ◦C. Protamine sulphate dissolved in
buffer A was added to the supernatant to a final concentration of
0.2% (w/v). After stirring for 30 min, the mixture was centrifuged
as before, and the supernatant fluid was chromatographed on a
column (1.9 cm × 7 cm) of Blue Sepharose CL-6B equilibrated
with buffer A. The column was washed with 100 ml of buffer A
and then with the same buffer containing 0.15 mM ADP. This
washing step was omitted in the purification of mutant and wild-
type isoforms of HmPFK-M. PFK activity was eluted with buffer
A containing 2 mM Fru-6-P and 2 mM ATP. Fractions of 2 ml
were collected and those showing PFK activity were pooled
and applied to a column (1.9 cm × 7.5 cm) of DEAE-trisacryl
equilibrated in buffer B (20 mM Tris/phosphate, 10 mM ammo-
nium sulphate, 10 mM NaF, 10 mM 2-mercaptoethanol, 1 mM
EDTA, 1 mM PMSF, 2.5 µg/ml leupeptin, 0.05 mM fructose
1,6-bisphosphate and 0.2 mM ATP, pH 7.5). The column was
washed with 100 ml of buffer B, and PFK activity was eluted
in 2 ml fractions with a linear gradient of buffer B and the same
buffer supplemented with 90 mM ammonium sulphate, 73.5 mM
potassium phosphate and 50 mM NaCl [28]. The final prepara-
tions were subjected to SDS/PAGE analysis on 10% (w/v) poly-
acrylamide gels and Coomassie Blue staining as described in [29],
and judged to be homogeneous by this criterion (Figure 1). For
kinetic studies, the purified preparations were dialysed against
10 mM Hepes, 0.5 mM PMSF, 2.5 µg/ml leupeptin and 20%
(v/v) glycerol, pH 7.5. The specific activities of the mutant PFKs
(32–58 units/mg) were in the range of those of the recombinant
wild-type enzymes [9], as were the amounts of pure protein ob-
tained (0.3–1 mg/litre of culture).
Enzyme activity assay
Total PFK activity was measured in an assay mixture con-
taining 50 mM Tris/HCl, 100 mM KCl, 5 mM MgCl2, pH 8.2,
5 mM Pi, 1 mM NH4 + , 0.1 mM cAMP, 1 µM Fru-2,6-P2,
0.15 mM NADH, 1 mM MgATP, 1.2 units of aldolase, 10 units of
triosephosphate isomerase, 1 unit of glycerol-3-phosphate dehy-
drogenase, 2–5 µl of the enzyme preparation and 6 mM Fru-6-P
in a final volume of 1 ml. Assays for kinetic studies were carried
out at pH 7.0 in 50 mM Hepes, 100 mM KCl, 5 mM MgCl2,
0.15 mM NADH, auxiliary enzymes, 2–5 µl of the purified
Figure 1 SDS/PAGE of purifiedmutant andwild-typeHmPFK-MandAtPFK-C
Samples containing 2–5 µg of purified enzymes were loaded per lane. The positions and
molecular masses of marker proteins are shown on the right.
enzyme, and the indicated concentrations of MgATP, effector and
Fru-6-P. In all cases, the reaction was started after a 5-min pre-
incubation by the addition of Fru-6-P, and was followed by
measuring the absorbance change at 340 nm at 25 ◦C. When PFK
activity was assayed during purification, glucose 6-phosphate
was added to Fru-6-P in proportions of 3:1 (mol/mol). Auxiliary
enzymes were desalted as described [20]. One unit of activity is
defined as the amount of enzyme catalysing the conversion of
1 µmol of substrate/min under the above conditions.
Fluorescence measurements
Titration of intrinsic PFK fluorescence with MgATP or citrate
was measured at 25 ◦C with a Perkin–Elmer LS50 luminescence
spectrometer. The excitation wavelength was set to 294 nm and
emission was recorded at 335 nm. The protein concentration was
6–20 µg/ml (within the linear portion of the fluorescence–concen-
tration curve) in 50 mM sodium phosphate, 1 mM EDTA, 25 mM
KCl, 0.2 mM dithiothreitol and 10 mM MgCl2, pH 7.0, and ex-
periments were performed by adding either small increments of
ligand or enzyme solution. Background readings were subtracted
and corrections were made to compensate for volume changes.
Results of the titrations were expressed as the fractional intrin-
sic fluorescence change F/Fo, where Fo and F are the corrected
fluorescence intensities in the absence and presence respectively
of ligand. Experimental errors in fluorescence measurements were
estimated to be less than 1%.
Other methods
Protein concentration was determined by Bradford’s dye-binding
method [30], using bovine γ -globulin as standard. Protection
against thermal denaturation was carried out essentially as des-
cribed previously [9], except that incubations in the presence of
increasing MgATP concentrations were performed at 55 ◦C for
50 min in 50 mM Hepes, 100 mM KCl and 5 mM MgCl2, pH 7.0.
RESULTS
Inhibition by MgATP
As shown in Figure 2, the C-terminal nonapeptide H763AHL-
EHISR, found to be essential for the inhibitory effect of MgATP
on rabbit muscle PFK [19], is highly conserved in all PFK-M
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Figure 2 Multiple alignment of the C-termini of mammalian PFKs
Sequences are from: ascites tumour cells (At), rat hypothalamus (Rh), human pancreatic islets
(Hp), rabbit brain (Rb), human muscle (Hm), canine muscle (Cm), rat pancreatic islets (Rp),
rabbit muscle (Rm), mouse liver (Ml), rat liver (Rl) and human liver (Hl). A nonapeptide reported
to be involved in the inhibition of RmPFK-M by ATP [19] is boxed. Histidine residues in this
region are in bold face. Black and grey boxes indicate positions in the alignment where the
same or a similar amino acid respectively is found in at least 10 out of the 11 listed sequences
(plurality 10). Deletions and point mutations introduced in either AtPFK-C or HmPFK-M are
indicated by arrows and asterisks respectively. A glutamate residue at position 777 of RbPFK-C
was identified by peptide sequencing, whereas the codon GTG for valine (instead of GAG for
glutamate) has been reported at the corresponding position in the cDNA sequence [39].
isoenzymes sequenced so far. Of the three histidine residues of
this sequence suggested [19] to be important for this effect, only
the third one is conserved in all PFK-L isoenzymes and in PFK-C
from human pancreatic islets, and none of them is present in other
PFK-C isoenzymes, although these latter isoforms contain one or
two histidines at nearby positions that could play a similar role.
We followed this hypothesis to examine the C-terminal motifs of
PFK-C involved in the allosteric effect of MgATP, and thus mu-
tated to alanine residues His-780 and His-781 of AtPFK-C, which
has a sequence identical with that of the mouse isoenzyme [9,31]
and which was shown to have regulatory properties similar to
those of the isoform in normal cells [9]. The corresponding cDNAs
were expressed in a PFK-deficient strain of S. cerevisiae [9],
and enzyme mutants were purified (Figure 1) and characterized.
However, neither the double mutant H780A/H781A nor the
single mutants H780A or H781A differed in their sensitivity to
inhibition by MgATP (Figure 3A) compared with the wild-type
enzyme. There were also no differences in Fru-6-P affinity and
co-operativity. We then resorted to HmPFK-M (Figure 3B) to
test the function of its C-terminal histidines. However, mutation
to alanine of the three potential histidines excluded a significant
role for these residues, since the sensitivity of the triple mutant
H764A/H766A/H769A to inhibition by MgATP scarcely deviated
from that of the wild-type enzyme (K i values of 3.2 and 2.6 mM
respectively). Nevertheless, deletion of the 17 C-terminal amino
acids (17) caused a dramatic decrease in inhibition by MgATP
(Figure 3B), similar to the results obtained by Valaitis et al. [19],
who made a similar truncation of the rabbit muscle enzyme with
Staphylococcus aureus V8 protease. An equivalent deletion of
AtPFK-C, 13 (Figure 3A), also shifted the inhibition curve
strikingly to the right, increasing the K i value by 6-fold (7.8 mM,
compared with 1.3 mM for the wild-type enzyme), whereas a 4
deletion had no effect on this property. This indicates that other
Figure 3 Effects of C-terminalmutations on the inhibition by ATP of AtPFK-C
and HmPFK-M
Assays were performed at pH 7.0 with 2 mM Fru-6-P. Activity is expressed relative to the
maximal activity obtained under these conditions for each enzyme. (A) AtPFK-C:, wild type;
, H780A/H781A;, 13;, L775A;, E776A;H17009, L775A/E776A. (B) HmPFK-M:, wild
type; , H764A/H766A/H769A; , 17; +, 12; , L767A; , E768A. Mutants H780A,
H781A and 4 of AtPFK-C gave MgATP inhibitions patterns that were coincident with that of
the wild-type enzyme; these were not included in the Figure for the sake of simplicity. The 17
mutant of HmPFK-M exhibited relative activity values of 0.64 and 0.25 at 11 and 12 mM MgATP
respectively.
motifs, different from the selected histidine residues but close to
the C-terminal end of PFK-C and located in a region equivalent
to that identified in PFK-M, are involved in the inhibitory effect of
MgATP on the former isoenzyme as well. A 12 deletion of PFK-
M, that eliminated the only histidine residue that is conserved in
all M and L isoforms, nevertheless did not affect the response to
MgATP (Figure 3B), narrowing the location of the key residues
to the pentapeptide H764AHLE (Figure 2). Alignments of the
C-termini of mammalian PFKs (Figure 2) showed that a leucine
and a glutamate located at contiguous positions (767 and 768
in HmPFK-M) are the only amino acids of this region that are
conserved in all PFK sequences. Both residues were found to
be responsible for the role of the C-terminus on the inhibitory
effect of MgATP, since either the L767A mutant or the E768A
mutant of HmPFK-M exhibited a marked decrease in this property
that was similar to that shown by the 17 mutant (Figure 3B).
In the case of AtPFK-C, replacement of both amino acids by
alanine was required (L775A/E776A mutant) to reproduce the
effect of the 13 deletion (Figure 3A), as each of the single
mutants L775A and E776A elicited a relatively mild right-shift
of the inhibition curve (K i values of 2.6 and 3.6 mM respectively,
compared with 1.3 mM for the wild-type enzyme). Neither of the
described mutations significantly modified the affinity of either
isoenzyme for MgATP at the catalytic site (Km values of PFK-M
mutants were 75–97 µM, compared with 77 µM for the wild-type
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Figure 4 Fru-6-P saturation curves for wild-type and mutant forms of
AtPFK-C (A) and HmPFK-M (B)
Assays were carried out at pH 7.0. The concentration of MgATP was fixed at 0.5 and 1 mM for
AtPFK-C and HmPFK-M respectively. The insets show S0.5 and h (nH) values calculated from
the data. When the assays were performed at 5 mM MgATP with either isoenzyme, the S0.5 and h
values of the mutant forms did not change significantly, whereas those of wild-type PFK-C were
3.5 mM and 3.8 respectively, and those of wild-type PFK-M were 2.6 mM and 2.9 respectively.
enzyme; those of the PFK-C mutants were 22–34 µM, compared
with 28 µM for the wild-type enzyme).
C-terminal mutations that desensitized PFK-C and PFK-M to
inhibition by MgATP increased moderately the affinity of both
isoenzyme types for Fru-6-P at 0.5–1 mM MgATP, but did not
significantly decrease the co-operativity of Fru-6-P, as indicated
by the corresponding S0.5 and h (Hill coefficient) values (Fig-
ure 4). For the mutant enzymes, these kinetic properties remained
virtually unchanged when the MgATP concentration was raised
to 5 mM, a highly inhibitory concentration for the wild-type
isoenzymes that markedly diminished their Fru-6-P affinity (see
legend to Figure 4). None of the generated mutations modified
catalysis noticeably, as shown by the kcat values of the mutants,
which varied from 204 to 261 s− 1 compared with 269 s− 1 for wild-
type PFK-M, and from 179 to 325 s− 1 compared with 235 s− 1 for
wild-type PFK-C.
Sensitivity to other effectors related to inhibition by MgATP
Citrate is an inhibitor of PFK that functions synergistically with
MgATP [18], and its effect was also reported to diminish sub-
stantially after C-terminal proteolysis of rabbit muscle PFK-M
[19]. Mutation studies indicated that the two effectors bind to sep-
arate sites [12,14], but the structural requirements for the syner-
gism between the regulators are unknown. We examined whether
the C-terminal motifs found to be critical for the ATP-mediated
inhibition of both isoenzymes are involved in the action of
Figure 5 Inhibition by citrate of wild-type and mutant forms of AtPFK-C and
HmPFK-M
Assays were carried out at pH 7.0. The Fru-6-P concentration was 2 mM. MgATP concentrations
were 0.5 and 1 mM for AtPFK-C and HmPFK-M respectively. Activity is expressed relative to
that obtained in the absence of citrate (V0). (A) AtPFK-C: , wild type; , 13; , L775A;
, E776A;H17009, L775A/E776A. (B) HmPFK-M:, wild type;, 17;, L767A;, E768A.
citrate (Figure 5). Under the conditions of the assay, PFK-M
was substantially more sensitive to inhibition by this metabolite
(K i 0.16 mM) than PFK-C, which was inhibited only at concen-
trations of citrate above 1 mM (after a small and apparently
insignificant activation burst), exhibiting a K i value of 1.7 mM.
Inhibition by citrate was practically abolished in PFK-C after the
13 deletion (Figure 5A), whereas it persisted in the more sensi-
tive M isoenzyme after the equivalent 17 deletion (Figure 5B),
although much higher concentrations of citrate were needed, with
a 30-fold increase in the K i value to 5 mM. The C-terminal
leucine and glutamate residues responsible for MgATP-mediated
inhibition contributed to inhibition of PFK-C by citrate in a similar
manner as for the inhibitory effect of MgATP, i.e. both of the single
mutants L775A and E776A moderately decreased the action
of citrate, whereas the double mutation L775A/E776A virtually
mimicked the de-inhibitory effect of the 13 deletion (Figure 5A).
In the M-isoenzyme, only the leucine residue appeared to be
involved in the action of citrate, as indicated by the marked shift
of the inhibition curve to the right shown by the L767A mutant,
resulting in a 17-fold higher K i value (2.77 mM) than for the wild-
type enzyme, and the lack of a significant change after the E768A
mutation (K i 0.24 mM) (Figure 5B).
Inhibition of PFK by MgATP is also known to occur synergi-
stically with the effect of the inhibitor phosphoenolpyruvate [18]
and to be counteracted by the strong activator Fru-2,6-P2 [17].
PFK-M was more sensitive to both effectors than PFK-C (Fig-
ure 6), with K i(phosphoenolpyruvate) values of 2.2 and 5.0 mM
respectively, and Kact(Fru-2,6-P2) values of 0.3 and 2.7 µM res-
pectively. However, none of the C-terminal deletions or point
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Figure 6 Effects of phosphoenolpyruvate (A) and Fru-2,6-P2 (B) on wild-
type and mutant forms of HmPFK-M and AtPFK-C
Assays were carried out at pH 7.0. Inhibition by phosphoenolpyruvate (P-enolpyruvate) was
performed under the conditions described in the legend to Figure 5, and activity is expressed
relative to that obtained in the absence of the inhibitor (V0). Fru-2,6-P2 activation was performed
at a Fru-6-P concentration of 0.8 mM and a MgATP concentration of 5 mM. The indicated
mutations did not significantly modify the extension of maximal Fru-2,6-P2 activation of each
isoenzyme. HmPFK-M:, wild type;, 17;, L767A;+, E768A. AtPFK-C:, wild type;
, 13;H17009, L775A/E776A.
mutations that greatly affected inhibition by MgATP of both iso-
enzymes were found to modify significantly the effects of phos-
phoenolpyruvate (Figure 6A) or Fru-2,6-P2 (Figure 6B) on either
PFK type.
Binding of MgATP and citrate
The involvement of the C-terminal region in the binding of
MgATP and citrate to PFK-M was examined by titration of in-
trinsic fluorescence of the 17 mutant and the wild-type en-
zyme in the presence of increasing concentrations of each of
these ligands. The M-type isoform was chosen because it showed
more drastic changes in MgATP-mediated inhibition upon mani-
pulation of this region, as well as higher sensitivity to inhibition
by citrate. As seen in Figure 7(A), MgATP quenched protein
fluorescence and gave a biphasic curve for the 17 mutant that
was virtually indistinguishable from that of the wild-type enzyme,
with maximum quenching with 10 mM MgATP of 50% and
47% respectively. This type of curve is consistent with the well
known binding of MgATP to both the high-affinity catalytic site
and the low-affinity inhibitory site [24], and their corresponding
apparent dissociation constants calculated from the data were
0.21 µM and 1.13 mM respectively for the mutant, which
Figure 7 Relative fluorescence intensity of wild-type and mutants17 and
L767A of HmPFK-M as a function of MgATP (A) and citrate (B) concentrations
Conditions were described in the Materials and methods section., wild type;, 17;H17009,
L767A. The fractional fluorescence change is plotted against increasing ligand concentration.
The kinetics of the decrease in fluorescence intensity induced by MgATP was biphasic, as shown
in the inset. K d-I and K d-II are the dissociation constants of the catalytic and inhibitory sites for
MgATP respectively.
were not significantly different from those of 0.19 µM and
1.04 mM respectively for the wild-type enzyme. Protection by
variable concentrations of MgATP against thermal denaturation
of the protein at 55 ◦C for 50 min gave apparent Kd values for the
second binding site of 2.0 mM and 1.4 mM for the 17 mutant
and the wild-type enzyme respectively (results not shown), i.e.
close to the values determined by changes in intrinsic protein
fluorescence. These data clearly indicated that, although the
C-terminal deletion desensitized PFK to inhibition by MgATP, it
did not modify its ability to bind this effector at its inhibitory site.
Figure 7(B) shows that citrate enhanced the fluorescence in-
tensity of PFK-M, suggesting that this ligand induces a different
conformation of the protein. The fluorescence changes increased
with increasing concentrations of citrate, and yielded a hyperbolic
curve that corresponded to an expected single binding site, with
a calculated Kd value of 14 µM for the wild-type enzyme. In
strong contrast with the observed lack of a role of the C-terminal
region of PFK-M in MgATP binding, the binding of citrate was
dramatically altered by the 17 deletion, as this mutant exhibited
a >200-fold decrease in the apparent affinity for this ligand with
respect to the wild-type enzyme, with a Kd value of 4.2 mM
and a sigmoidal binding curve. Furthermore, the L767A mutant
also showed a marked decrease in citrate binding (Kd 1.6 mM)
that paralleled its effect on inhibition by citrate (Figure 5B). The
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fact that this point mutation reduced both phenomena to a some-
what lower degree than the 17 deletion suggests that other,
unidentified residues of the C-terminal tail region of PFK-M may
also participate in the action of citrate. As also shown in Fig-
ure 7(B), maximum fluorescence enhancement (approx. 11%)
was not changed significantly by either of these mutations.
DISCUSSION
The series of deletions and single point mutations of PFK-M
examined here has led us to identify the contiguous residues Leu-
767 and Glu-768 as being responsible for the involvement of
the C-terminal region of the enzyme in allosteric inhibition by
MgATP, with the replacement of either of these residues being
sufficient to desensitize the enzyme to the inhibitor. Although
this region exhibits marked variability among PFK sequences
from eukaryotic sources, we observed that it performs a similar
function in the more inhibitable C-type isoenzyme. The identified
amino acids are the only motifs that are conserved in the C-termini
of all mammalian PFK sequences, and they were also found to be
involved in inhibition by MgATP of PFK-C (positions 775 and
776), although they contribute somewhat differently in this case,
since their simultaneous mutation was required for a substantial
decrease in the effect of MgATP. The decreased sensitivity to
MgATP was not due to a lack of binding of this inhibitor to the
allosteric site, as fluorescence titration and protection against irre-
versible thermal denaturation were not affected by deletion of the
final 17 residues of PFK-M (and therefore most probably not
by the mutation of the conserved residues of this region either).
Neither does desensitization to MgATP appear to be related to
a marked increase in Fru-6-P affinity that would reduce MgATP
inhibition to such an extent, since none of the insensitive mutants
exhibited a substantial change in this property (<50% decrease in
their S0.5 values for Fru-6-P; Figure 4). The simplest interpretation
is that these mutations prevent the conformational change of the
enzyme to a less active form induced by binding of MgATP to
its inhibitory allosteric site. Leu-775 and Glu-776 of PFK-C, and
Leu-767 of PFK-M, are also involved in inhibition by citrate.
However, our binding studies with the latter isoenzyme indicate
that its C-terminal region, and at least the Leu-767 residue in
particular, functions differently in the action of the two allosteric
effectors. Thus, whereas this region does not contribute to the
binding of MgATP but is involved in the subsequent propagation
of the allosteric signal to the catalytic site, it is essential for the
binding of citrate (Figure 7). Therefore the two regulators can
act together, even involving the same amino acid, without mutual
binding exclusion.
Elucidation of the structural interactions exerted by the identi-
fied motifs to account for their effects on inhibition by MgATP
and citrate awaits determination of the three-dimensional structure
of the mammalian enzyme. Nevertheless, the identification of
C-terminal residues that are critical for the action of both inhibitors
provides a tentative molecular basis for their synergistic operation.
Both the ATP inhibitory and the citrate binding sites have been
proposed to have developed from the phosphoenolpyruvate/ADP
allosteric site of E. coli PFK [14], such that the two allosteric
sites shared by each subunit pair of the bacterial tetramer [11]
evolved to form new specific sites comprising residues from the N-
and C-terminal halves of the mammalian enzyme after the process
of gene duplication, fusion and mutation [10,32]. Site-directed
mutagenesis [12,14] and chemical modification [33] studies
suggest that one of the prokaryotic allosteric sites was the origin of
the ATP inhibitory site, which would be close to the peptide region
connecting the two halves of the mammalian pseudodimeric
subunit, whereas the citrate site is derived from the second
prokaryotic allosteric site, and so it would be located at the other
end of the eukaryotic subunit near the N- and C-termini. The
spatial location of the C-terminal extension of mammalian PFK
implied by this model, presumably closer to the citrate site than
to the MgATP inhibitory site, agrees with our finding that this
region participates in the binding of the former, but not the latter.
Whether the involved motifs of the C-termini interact directly
with citrate, or induce an optimal binding conformation without
being part of the binding site itself, remains to be elucidated.
Although some synergism has been reported [18] between
MgATP inhibition and the inhibitor phosphoenolpyruvate, the
lack of effect of the C-terminal mutations of PFK-M and PFK-C
on the action of phosphoenolpyruvate indicates that it utilizes a
different structural pathway. Its antagonistic binding to muscle
PFK with regard to citrate [18] suggested that they share a
common site. The evolution of the prokaryotic allosteric site also
involved a substantial loss of affinity for phosphoenolpyruvate,
which became a less physiologically relevant regulator in animal
cells in view of its low intracellular concentrations, generally
within the micromolar range [34–36], in comparison with the
millimolar K i values of mammalian PFK isoenzymes for this
metabolite (Figure 6A).
Mutagenesis of the C-terminal residues found to be critical for
inhibition of both PFK-M and PFK-C by MgATP allowed the
dissection of this regulatory effect and Fru-6-P co-operativity, in
conjunction with Fru-2,6-P2 activation, into separate phenomena,
since desensitization to the inhibitor did not modify the other
two properties. These results agree with recent findings obtained
by mutations of the non-regulatory PFK from Dictyostelium
discoideum, which suggested that the action of the inhibitor
MgATP is decoupled from Fru-6-P co-operativity, and that stim-
ulation by Fru-2,6-P2 operates on the same R/T conformational
transition that accounts for co-operativity [20]. Nevertheless,
the latter observations were made by generating co-operativity
and Fru-2,6-P2 stimulation in a previously non-allosteric PFK,
whereas in the present work inhibition by MgATP was eliminated
from two normal allosteric isoforms of mammalian PFK without
changes in the other two effects. This provides evidence that
although MgATP clearly interacts with the action of Fru-6-P
[2,15,16] and Fru-2,6-P2 [17], its inhibitory effect is brought
about by an allosteric transition distinct from that involved in
Fru-6-P co-operativity and activation by Fru-2,6-P2. Therefore
the operation of these regulatory mechanisms in mammalian PFK
does not follow the concerted model of Monod et al. [37], which
assumes a unique allosteric transition between two (and only two)
conformations.
The high variability of the sequence of the C-terminal extension
of eukaryotic PFK appears to serve a variety of functions in differ-
ent isoenzymes. In yeast, this region has been reported to be ne-
cessary for the three-dimensional structure and correct assembly
of subunits [38]. In the slime mould D. discoideum, this part of
the sequence was found to be responsible for the lack of allosteric
transitions that characterizes this particular isoform [20]. In mam-
malian cells, the data reported herein show that the C-terminus
contains specific motifs that were critical in the evolutionary pro-
cess of endowing PFK isoenzymes with sensitivity to new allos-
teric signals for the regulation of energy metabolism, such as
MgATP and citrate.
We are indebted to Dr K. Tornheim for helpful comments and critical reading of the
manuscript. We also thank V. Sa´nchez for her contribution to the construction and
purification of several PFK-C mutants, and P. Lo´pez and G. Lucian˜ez for their help in
some experiments. This work was supported by grants from from the Direccio´n General de
Investigacio´n del Ministerio de Ciencia y Tecnolog´ıa (PB98-0058) and Instituto de Salud
Carlos III, Red de Centros RCMN (C03/08).
c© 2004 Biochemical Society
84 O. H. Mart´ınez-Costa and others
REFERENCES
1 Uyeda, K. (1979) Phosphofructokinase. Adv. Enzymol. Relat. Areas Mol. Biol. 48,
193–244
2 Sols, A. (1981) Multimodulation of enzyme activity. Curr. Top. Cell. Regul. 19, 77–101
3 Kemp, R. G. and Foe, L. G. (1983) Allosteric regulatory properties of muscle
phosphofructokinase. Mol. Cell. Biochem. 57, 147–154
4 Dunaway, G. A. and Kasten, T. P. (1987) Nature of the subunits of the
6-phosphofructo-1-kinase isoenzymes from rat tissues. Biochem. J. 242, 667–671
5 Yaney, G. C., Schultz, V., Cunningham, B. A., Dunaway, G. A., Corkey, B. E. and
Tornheim, K. (1995) Phosphofructokinase isozymes in pancreatic islets and clonal
β-cells (INS-1). Diabetes 44, 1285–1289
6 Sa´nchez-Mart´ınez, C. and Arago´n, J. J. (1997) Analysis of phosphofructokinase subunits
and isozymes in ascites tumour cells and its original tissue, murine mammary gland.
FEBS Lett. 409, 86–90
7 Foe, L. G. and Kemp, R. G. (1985) Isolation and characterization of phosphofructokinase
C from rabbit brain. J. Biol. Chem. 260, 726–730
8 Dunaway, G. A., Kasten, T. P., Sebo, T. and Trapp, R. (1988) Analysis of the
phosphofructokinase subunits and isoenzymes in human tissues. Biochem. J. 251,
677–683
9 Sa´nchez-Mart´ınez, C., Este´vez, A. M. and Arago´n, J. J. (2000) Phosphofructokinase C
isozyme from ascites tumor cells: cloning, expression, and properties. Biochem. Biophys.
Res. Commun. 271, 635–640
10 Poorman, R. A., Randolph, A., Kemp, R. G. and Heinrikson, R. L. (1984) Evolution of
phosphofructokinase: gene duplication and creation of new effector sites. Nature
(London) 309, 467–469
11 Schirmer, T. and Evans, P. R. (1990) Structural basis of the allosteric behaviour of
phosphofructokinase. Nature (London) 343, 140–145
12 Li, Y., Rivera, D., Ru, W., Gunasekera, D. and Kemp, R. G. (1999) Identification of
allosteric sites in rabbit phosphofructo-1-kinase. Biochemistry 38, 16407–16412
13 Chang, S. H. and Kemp, R. G. (2002) Role of Ser530, Arg292, and His662 in the allosteric
behavior of rabbit muscle phosphofructokinase. Biochem. Biophys. Res. Commun. 290,
670–675
14 Kemp, R. G. and Gunasekera, D. (2002) Evolution of the allosteric ligand sites of
mammalian phosphofructo-1-kinase. Biochemistry 41, 9426–9430
15 Frieden, C., Gilbert, H. R. and Bock, P. E. (1976) Phosphofructokinase. III. Correlation
of the regulatory kinetic and molecular properties of the rabbit muscle enzyme.
J. Biol. Chem. 251, 5644–5647
16 Reinhart, G. D. and Lardy, H. A. (1980) Rat liver phosphofructokinase: kinetic activity
under near-physiological conditions. Biochemistry 19, 1477–1484
17 Van Schaftingen, E. (1987) Fructose 2,6-bisphosphate. Adv. Enzymol.
Relat. Areas Mol. Biol. 59, 315–395
18 Colombo, G., Tate, P. W., Girotti, A. W. and Kemp, R. G. (1975) Interaction of inhibitors
with muscle phosphofructokinase. J. Biol. Chem. 250, 9404–9412
19 Valaitis, A. P., Foe, L. G. and Kemp, R. G. (1987) Desensitization of muscle
phosphofructokinase to ATP inhibition by removal of a carboxyl-terminal
heptadecapeptide. J. Biol. Chem. 262, 5044–5048
20 Santamar´ıa, B., Este´vez, A. M., Mart´ınez-Costa, O. H. and Arago´n, J. J. (2002) Creation of
an allosteric phosphofructokinase starting with a nonallosteric enzyme. The case of
Dictyostelium discoideum phosphofructokinase. J. Biol. Chem. 277, 1210–1216
21 Setlow, B. and Mansour, T. E. (1970) Studies on heart phosphofructokinase. Nature of the
enzyme desensitized to allosteric control by photo-oxidation and by acylation with
ethoxyformic anhydride. J. Biol. Chem. 245, 5524–5533
22 Rao, G. S. J., Wariso, B. A., Cook, P. F., Hofer, H. W. and Harris, B. G. (1987) Reaction of
Ascaris suum phosphofructokinase with diethylpyrocarbonate. Inactivation and
desensitization to allosteric modulation. J. Biol. Chem. 262, 14068–14073
23 Bock, P. E. and Frieden, C. (1976) Phosphofructokinase. II. Role of ligands in
pH-dependent structural changes of the rabbit muscle enzyme. J. Biol. Chem. 251,
5637–5643
24 Pettigrew, D. W. and Frieden, C. (1970) Binding of regulatory ligands to rabbit muscle
phosphofructokinase. A model for nucleotide binding as a function of temperature and
pH. J. Biol. Chem. 254, 1887–1895
25 Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory
Manual, 2nd edn, Cold Spring Harbor Press, Cold Spring Harbor, NY
26 Este´vez, A. M., Heinisch, J. J. and Arago´n, J. J. (1995) Functional complementation of
yeast phosphofructokinase mutants by the non-allosteric enzyme from Dictyostelium
discoideum. FEBS Lett. 374, 100–104
27 Raben, N., Exelbert, R., Spiegel, R., Sherman, J. B., Nakajima, H., Plotz, P. and Heinisch,
J. (1995) Functional expression of human mutant phosphofructokinase in yeast: genetic
defects in French Canadian and Swiss patients with phosphofructokinase deficiency.
Am. J. Hum. Genet. 56, 131–141
28 Etiemble, J., Simeon, J., Buc, H. A., Picat, C., Boulard, M. and Boivin, P. (1983) A
liver-type mutation in a case of pronounced erythrocyte phosphofructokinase deficiency
without clinical expression. Biochim. Biophys. Acta 759, 236–242
29 Mart´ınez-Costa, O. H., Este´vez, A. M., Sa´nchez, V. and Arago´n, J. J. (1994) Purification
and properties of phosphofructokinase from Dictyostelium discoideum. Eur. J. Biochem.
226, 1007–1017
30 Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72,
248–254
31 Gunasekera, D. and Kemp, R. G. (1999) Cloning, sequencing, expression, and
purification of the C isozyme of mouse phosphofructokinase. Protein Expression Purif. 16,
448–453
32 Fothergill-Gilmore, L. A. (1987) Evolution in glycolysis. Biochem. Soc. Trans. 15,
993–995
33 Kemp, R. G., Fox, R. W. and Latshaw, S. P. (1987) Amino acid sequence at the citrate
allosteric site of rabbit muscle phosphofructokinase. Biochemistry 26, 3443–3446
34 Jacobasch, G., Minakami, S. and Rapoport, S. M. (1974) Glycolysis of the erythrocyte.
In Cellular and Molecular Biology of Erythrocytes (Yoshikawa, H. and Rapoport, S., eds.),
pp. 55–92, Urban & Schwarzenberg, Mu¨nchen
35 Fel´ıu, E., Hue, L. and Hers, H.-G. (1977) Regulation in vitro and in vivo of adenosine
3′ :5′-monophosphate-dependent inactivation of rat-liver pyruvate kinase type L.
Eur. J. Biochem. 81, 609–617
36 Gonza´lez-Mateos, F., Go´mez, M.-E., Garc´ıa-Salguero, L., Sa´nchez, V. and Arago´n, J. J.
(1993) Inhibition of glycolysis by amino acids in ascites tumor cells. Specificity and
mechanism. J. Biol. Chem. 268, 7809–7817
37 Monod, J., Wyman, J. and Changeux, J.-P. (1965) On the nature allosteric transitions:
a plausible model. J. Mol. Biol. 12, 88–118
38 Edelmann, A., Kirchberger, J., Heinisch, J. J. and Kopperschla¨ger, G. (2002) C-terminal
modification of 6-phosphofructo-1-kinase from Saccharomyces cerevisiae and its
influence on enzyme structure and activity. Biochem. Biophys. Res. Commun. 295,
992–999
39 Li, Y., Valaitis, A. P., Latshaw, S. P., Kwiatkowska, D., Tripathi, R. L., Campbell, M. C. and
Kemp, R. G. (1994) Structure and expression of the cDNA for the C isozyme of
phophofructo-1-kinase form rabbit brain. J. Biol. Chem. 269, 5781–5787
Received 9 July 2003/2 September 2003; accepted 16 September 2003
Published as BJ Immediate Publication 16 September 2003, DOI 10.1042/BJ20031032
c© 2004 Biochemical Society
